Compare Abrdn Physical Platinum Shares ETF (PPLT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Abrdn Physical Platinum Shares ETF trades at $14.56 (market cap $2.00B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.4× Abrdn Physical Platinum Shares ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Abrdn Physical Platinum Shares ETF for 43 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PPLT | TVTX | |
|---|---|---|
Market Cap | $2.00B | $4.88B |
Volume | 1,178,871 | 1,668,577 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $67.52 |
52-Week Low | $13.73 | $26.79 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT, the abrdn Physical Platinum Shares ETF, trades at $15.05, down 1.44% with a bearish technical outlook. Moving averages signal strong selling pressure while oscillators remain neutral. Recent news highlights platinum's underperformance in the precious metals rally, with some analysts viewing it as a potential catch-up trade opportunity despite current bearish technicals.
The ETF faces headwinds from platinum's term structure in contango, suggesting adequate supply. Historical seasonality offers some counterpoint to the bearish outlook. Investment opportunity exists if platinum catches up to gold and silver's recent rally, though supply dynamics and technical weakness present near-term risks.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
